MEDFORD, NY--(Marketwire - December 17, 2007) - Chembio Diagnostics, Inc. (OTCBB: CEMI) (“Chembio” or the “Company”) announced today that Pall Corporation (“Pall”) has advised Chembio that Chembio’s patented Dual Path Platform (“DPP™") point-of-care test system has achieved the performance objectives of the feasibility study entered into by the companies in July 2007.
